Literature DB >> 35309182

Peri-operative management of an adult with POLG-related mitochondrial disease.

A Valent1, L Delorme1, E Roland1, C Lambe2, S Sarnacki3, P Cattan4, B Plaud1.   

Abstract

POLG-related mitochondrial disease is a rare mitochondrial disorder that is potentially associated with anaesthetic complications such as propofol-related infusion syndrome. A 19-year-old man with mitochondrial DNA deletions and POLG-related disorders presented for an elective robotic Heller-Dor myotomy for the treatment of oesophageal pseudo-achalasia associated with severe gastro-oesophageal reflux. The fasting period was minimised to reduce the risk of metabolic stress. The anaesthetic technique included a rapid sequence induction with propofol and rocuronium, a remifentanil and sevoflurane-based general anaesthesia with multimodal monitoring and peri-operative lactate-free intravenous fluids with added dextrose. The patient did not experience propofol-related infusion syndrome but did have delayed tracheal extubation due to residual neuromuscular blockade requiring a second dose of sugammadex. This report demonstrates the safety of single-use, low-dose propofol in this patient group. Patients with POLG-related mitochondrial disease may be at risk of prolonged neuromuscular blockade, and appropriate dosing of neuromuscular blocking agents with monitoring of neuromuscular blockade is strongly encouraged.
© 2022 Association of Anaesthetists.

Entities:  

Keywords:  POLG; mitochondrial disease; prolonged NMB risk‐factors; propofol infusion syndrome

Year:  2022        PMID: 35309182      PMCID: PMC8918921          DOI: 10.1002/anr3.12159

Source DB:  PubMed          Journal:  Anaesth Rep        ISSN: 2637-3726


  9 in total

1.  Sensitivity to mivacurium in a patient with mitochondrial myopathy.

Authors:  M Naguib; A A el Dawlatly; M Ashour; M al-Bunyan
Journal:  Anesthesiology       Date:  1996-06       Impact factor: 7.892

2.  Anaesthesia and mitochondrial disease.

Authors:  J J Wallace; H Perndt; M Skinner
Journal:  Paediatr Anaesth       Date:  1998       Impact factor: 2.556

Review 3.  Propofol Is Mitochondrion-Toxic and May Unmask a Mitochondrial Disorder.

Authors:  Josef Finsterer; Marlies Frank
Journal:  J Child Neurol       Date:  2016-08-03       Impact factor: 1.987

4.  Analytic reviews: propofol infusion syndrome in the ICU.

Authors:  Daniel A Diedrich; Daniel R Brown
Journal:  J Intensive Care Med       Date:  2011 Mar-Apr       Impact factor: 3.510

Review 5.  Anesthetic considerations in patients with mitochondrial defects.

Authors:  Julie Niezgoda; Phil G Morgan
Journal:  Paediatr Anaesth       Date:  2013-03-28       Impact factor: 2.556

6.  Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy.

Authors:  J Finsterer; U Stratil; R Bittner; P Sporn
Journal:  Can J Anaesth       Date:  1998-08       Impact factor: 5.063

Review 7.  Mitochondrial disorders and general anaesthesia: a case series and review.

Authors:  E J Footitt; M D Sinha; J A J Raiman; A Dhawan; S Moganasundram; M P Champion
Journal:  Br J Anaesth       Date:  2008-02-19       Impact factor: 9.166

Review 8.  Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

Authors:  Sumit Parikh; Amy Goldstein; Amel Karaa; Mary Kay Koenig; Irina Anselm; Catherine Brunel-Guitton; John Christodoulou; Bruce H Cohen; David Dimmock; Gregory M Enns; Marni J Falk; Annette Feigenbaum; Richard E Frye; Jaya Ganesh; David Griesemer; Richard Haas; Rita Horvath; Mark Korson; Michael C Kruer; Michelangelo Mancuso; Shana McCormack; Marie Josee Raboisson; Tyler Reimschisel; Ramona Salvarinova; Russell P Saneto; Fernando Scaglia; John Shoffner; Peter W Stacpoole; Carolyn M Sue; Mark Tarnopolsky; Clara Van Karnebeek; Lynne A Wolfe; Zarazuela Zolkipli Cunningham; Shamima Rahman; Patrick F Chinnery
Journal:  Genet Med       Date:  2017-07-27       Impact factor: 8.822

Review 9.  POLG-related disorders and their neurological manifestations.

Authors:  Shamima Rahman; William C Copeland
Journal:  Nat Rev Neurol       Date:  2019-01       Impact factor: 42.937

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.